INmune Bio, Inc. (INMB)
1.21
-0.01
(-0.82%)
USD |
NASDAQ |
Jun 10, 16:00
1.20
-0.01
(-0.83%)
Pre-Market: 09:01
INmune Bio Shareholders Equity (Quarterly) : 19.62M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 19.62M |
| December 31, 2025 | 23.52M |
| September 30, 2025 | 25.38M |
| June 30, 2025 | 28.87M |
| March 31, 2025 | 29.67M |
| December 31, 2024 | 32.10M |
| September 30, 2024 | 38.68M |
| June 30, 2024 | 37.08M |
| March 31, 2024 | 29.02M |
| December 31, 2023 | 38.14M |
| September 30, 2023 | 44.73M |
| June 30, 2023 | 50.65M |
| March 31, 2023 | 55.30M |
| December 31, 2022 | 60.10M |
| September 30, 2022 | 63.71M |
| June 30, 2022 | 69.93M |
| March 31, 2022 | 75.64M |
| December 31, 2021 | 80.22M |
| September 30, 2021 | 88.26M |
| Date | Value |
|---|---|
| June 30, 2021 | 43.23M |
| March 31, 2021 | 63.56M |
| December 31, 2020 | 38.75M |
| September 30, 2020 | 41.21M |
| June 30, 2020 | 21.68M |
| March 31, 2020 | 22.41M |
| December 31, 2019 | 23.61M |
| September 30, 2019 | 24.71M |
| June 30, 2019 | 26.84M |
| March 31, 2019 | 22.86M |
| December 31, 2018 | 16.54M |
| September 30, 2018 | 17.47M |
| June 30, 2018 | 18.03M |
| March 31, 2018 | 18.63M |
| December 31, 2017 | 18.10M |
| September 30, 2017 | 1.873M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | -0.1492M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Sangamo Therapeutics, Inc. | -18.96M |
| Arrowhead Pharmaceuticals, Inc. | 613.98M |
| Oncolytics Biotech, Inc. | -5.13M |
| Sarepta Therapeutics, Inc. | 1.505B |
| Anixa Biosciences, Inc. | 15.08M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 25.82M |
| Total Liabilities (Quarterly) | 6.194M |
| Debt to Equity Ratio | 0.0769 |
| Current Ratio | 4.236 |
| Net Debt Paydown Yield | -0.75% |